Asleep at the Switch
This article was originally published in RPM Report
Drug reviews by FDA don't always go smoothly. In the case of Neurocrine Biosciences, things got really bumpy when implementation of an electronic NDA filing system came as the drug center was reorganizing its review divisions. Neurocrine says both factored into the delay of its investigational sleep agent indiplon.
You may also be interested in...
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.
Transparency On COVID Vaccine Clinical Holds Needed, Sharfstein Says; US FDA Advisory Cmtes Offer Venue
Former acting Commissioner Josh Sharfstein argues that while agency officials have done a commendable job in overall communication on COVID vaccine development, more information is needed on the clinical holds.
As US FDA recovers from aducanumab and looks towards an advisory committee on Pfizer’s COVID vaccine, it’s worth reflecting on how Office of Vaccine Research & Review Director Marion Gruber created positive turning points for the agency during a general discussion of vaccine approval standards at the VRBPAC.